KR20230156689A - 지속형 글루카곤 유사 폴리펩티드-1(glp-1) 수용체작용제 및 사용 방법 - Google Patents

지속형 글루카곤 유사 폴리펩티드-1(glp-1) 수용체작용제 및 사용 방법 Download PDF

Info

Publication number
KR20230156689A
KR20230156689A KR1020237023789A KR20237023789A KR20230156689A KR 20230156689 A KR20230156689 A KR 20230156689A KR 1020237023789 A KR1020237023789 A KR 1020237023789A KR 20237023789 A KR20237023789 A KR 20237023789A KR 20230156689 A KR20230156689 A KR 20230156689A
Authority
KR
South Korea
Prior art keywords
silver
isolated polypeptide
spacer
positions
aib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237023789A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 블랙웰
베드 피. 스리바스타바
마크 폴릭
Original Assignee
아이투오 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이투오 테라퓨틱스, 인코포레이티드 filed Critical 아이투오 테라퓨틱스, 인코포레이티드
Publication of KR20230156689A publication Critical patent/KR20230156689A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237023789A 2020-12-17 2021-12-16 지속형 글루카곤 유사 폴리펩티드-1(glp-1) 수용체작용제 및 사용 방법 Pending KR20230156689A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126736P 2020-12-17 2020-12-17
US63/126,736 2020-12-17
PCT/US2021/063920 WO2022133148A1 (en) 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Publications (1)

Publication Number Publication Date
KR20230156689A true KR20230156689A (ko) 2023-11-14

Family

ID=80123475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023789A Pending KR20230156689A (ko) 2020-12-17 2021-12-16 지속형 글루카곤 유사 폴리펩티드-1(glp-1) 수용체작용제 및 사용 방법

Country Status (13)

Country Link
US (2) US12084485B2 (cg-RX-API-DMAC10.html)
EP (1) EP4263587A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024502740A (cg-RX-API-DMAC10.html)
KR (1) KR20230156689A (cg-RX-API-DMAC10.html)
CN (1) CN116917311A (cg-RX-API-DMAC10.html)
AR (1) AR124395A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021400738A1 (cg-RX-API-DMAC10.html)
CA (1) CA3202389A1 (cg-RX-API-DMAC10.html)
IL (1) IL303686A (cg-RX-API-DMAC10.html)
MX (1) MX2023007224A (cg-RX-API-DMAC10.html)
TW (1) TW202237628A (cg-RX-API-DMAC10.html)
WO (1) WO2022133148A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202306290B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AU2024218747A1 (en) * 2023-02-10 2025-08-28 Hangzhou Sciwind Biosciences Co., Ltd. Polypeptide and derivative thereof, composition, and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256056A1 (en) 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
JP6165168B2 (ja) * 2011-12-22 2017-07-19 ファイザー・インク 抗糖尿病化合物
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR20240037175A (ko) * 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
CA3025592A1 (en) * 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物

Also Published As

Publication number Publication date
JP2024502740A (ja) 2024-01-23
EP4263587A1 (en) 2023-10-25
US12084485B2 (en) 2024-09-10
WO2022133148A1 (en) 2022-06-23
CN116917311A (zh) 2023-10-20
TW202237628A (zh) 2022-10-01
ZA202306290B (en) 2026-03-25
AR124395A1 (es) 2023-03-22
AU2021400738A1 (en) 2023-07-13
IL303686A (en) 2023-08-01
US20230063420A1 (en) 2023-03-02
MX2023007224A (es) 2023-09-05
CA3202389A1 (en) 2022-06-23
US20250034225A1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
JP2023174675A (ja) グルカゴン受容体選択的ポリペプチド及びその使用方法
JP7636321B2 (ja) ヒトアミリンアナログペプチド及び使用方法
IL297375A (en) Controlled-release cnp agonists with low npr–c binding
US12122816B2 (en) Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
US20250034225A1 (en) Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use
WO2017200944A1 (en) Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
RU2839688C2 (ru) Полипептиды аналога амилина человека и способы их применения
KR20230039604A (ko) 지속형 글루카곤 수용체 선택적 펩타이드 및 사용 방법
EA052603B1 (ru) Селективные к рецептору глюкагона пептиды длительного действия и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902